Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ELUTIA INC. (ELUT)

Elutia secures up to $26 million to fund NXT-41x; Q2 sales fall to $2.4 million

Mixed Impact 4 of 5 earnings Written later

Elutia reported second quarter 2026 results with net sales down to $2.4 million from $2.7 million, while its net loss narrowed to $7.6 million from $9.6 million. The company said it has secured up to $26 million in additional capital to fund NXT-41x through anticipated FDA clearance and its first full year of commercial launch, without an equity offering, which matters to shareholders because it reduces near-term dilution risk.

Key points

  • Q2 2026 net sales were $2.4 million versus $2.7 million a year earlier, due mainly to a $0.7 million reduction in SimpliDerm revenue from a contract manufacturer production disruption.
  • Adjusted EBITDA was a loss of $4.6 million versus a loss of $3.0 million in the prior-year quarter.
  • Up to $26 million of capital includes a $15 million credit facility ($10 million funded at closing) and up to $11 million from the SimpliDerm divestiture.
  • Cash and cash equivalents were $19.9 million at June 30, 2026, and the company expects the full $8 million BioEnvelope escrow to be released in the fourth quarter of 2026.

The filing

CompanyELUTIA INC. (ELUT)
Form8-K, current report
Filed with the SECAug 13, 2026, 4:15 PM ET
Accession number0001104659-26-095934

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.